Analyst Upgrades

• Chesapeake (CHK) to buy from hold at Canaccord.
• Biogen (BIIB) and Regeneron (REGN) to outperform from sector perform at RBC Capital.
• Caribou Coffee (CBOU) to outperform from neutral and Encore Energy (ENP) to neutral from underperform at RW Baird.
• Fluor (FLR) to market perform from underperform at BMO Capital.
• Hornbeck Offshore (HOS) to conviction buy from neutral at Goldman.
• Saks (SKS) and Zale (ZLC) to neutral from underperform at BofA/Merrill.

Our recommendations for the Buyback Premium Portfolio center on a collection of five stocks that we believe, as a group, will outperform the market this month.

The Buyback Premium Portfolio has beat the S&P 500 by more than 72% since its inception (August 2, 2000)! It is up 54.87% since inception vs. a decline of 17.90% in the S&P 500. For the month of November, the portfolio gained 3.41% vs. a decline of 0.23% in the S&P 500.

Analyst Upgrades

• Goldman upgraded Jones Lang LaSalle (JLL) to buy from neutral.
• Credit Suisse upgraded Pulte Group (PHM) to neutral from underperform. Note that Citigroup downgraded the stock.
• Ameristar Casinos (ASCA) was upgraded to neutral from sell at Merriman.
• Citigroup upgraded Kimco Realty (KIM) to hold from sell.
• Mistras (MG) was upgraded to buy from hold at KeyBanc.
• Devon Energy (DVN) was upgraded to outperform from neutral at Macquarie.
• Garmin (GRMN) was upgraded to outperform from sector perform at PacCrest.

Durable goods sounded good on the surface until the transportation component was removed and after a look at many sectors in business spending. The trend belief is now that quantitative easing (QE2) is going to be lower in dollars and be spread out over a longer period. This all leads to some give-back for stocks, and longer-term bond yields rose as well.

Here were today's unofficial closing bell levels:

DJIA
NASDAQ
S&P500

Top Analyst Calls

Analyst Upgrades

• Deutsche Bank upgraded Smurfit-Stone (SSCC) to buy from hold after raising its estimates for containerboard names and upped its target for shares to $28 from $22. The firm also raised its price target for International Paper (IP) to $38 from $32, for Packaging Corp. (PKG) to $33 from $28, for Temple-Inland (TIN) to $31 from $28, for Greif (GEF) to $67 from $65, and for Rock-Tenn (RKT) to $70 from $65. All stocks are buy rated.
• ThinkEquity upgraded VMware (VMW) to buy from hold and has a $90 price target on the stock. The firm expects VMware to benefit from increased virtual infrastructure adoption and improving vSphere solutions.
• Needham upgraded Cavium Networks (CAVM) to strong buy from buy, citing the recent pullback in shares following Cisco's (CSCO) cautious commentary. The firm has a $37 target on the stock.
• Intercontinental Exchange (ICE) was upgraded to outperform from neutral at Credit Suisse.
• MedAssets (MDAS) was upgraded to buy from hold at Auriga.
• Brookfield Properties (BPO) was upgraded to buy from hold at Citigroup.

Biogen Idec (BIIB) improved its bullish prospects today as it announced earnings of $1.31 per share -- well above the Wall Street consensus estimate of $1.12 -- and raised its 2010 earnings outlook.

Total revenue for last quarter -- thanks in large part to better-than-expected sales of Biogen's multiple sclerosis drug Avonex -- came in at $1.2 billion, up 11% year over year.

Perhaps most exciting, however, was Biogen's announcement that it is raising its guidance for 2010 earnings to $4.70 per share, up from the current consensus of $4.57.

It appears that U.S.-based drug makers and cigarette companies caught the attention of traders Tuesday -- at least, that's what they're searching for.

If you want to know what stocks traders are interested in right now at this very second, you need look no further than what's hot in Google.

Here's what's hot Friday:

Biogen Idec (BIIB - option chain) stock is trading lower today on news that an FDA advisory committee recommended approval of Novartis' (NVS) FTY720 treatment for patients with relapsing multiple sclerosis. NVS said the drug worked better in trials than BIIB's drug Avonex. If you think this stock won't be rising too far in the coming months, then it could be a good time to look at a bearish hedged play on BIIB.

This morning, BIIB opened at $47.39. So far today the stock has hit a high of $47.62 and a low of $46.52. As of 12:30, BIIB is trading at $46.64, down $1.50 (-3.1%). The chart for BIIB looks neutral and S&P gives BIIB a neutral 3 STARS (out of 5) hold ranking.

Analyst Upgrades

• Scotia Capital upgraded Apple (AAPL) to outperform from sector perform, citing valuation, potential increased iPhone distribution and iPad upside. The firm's two-year price target is $325.
• UBS upgraded Parker-Hannifin (PH) to neutral from sell following the company's better-than-expected Q3 report.
• Piper Jaffray upgraded Arkansas Best (ABFS) to neutral from underweight after the Teamsters union announced a tentative agreement with the company. The firm has a $33 price target for shares.
• Harley-Davidson (HOG) was upgraded to market perform from underperform at Raymond James.
• Allegheny Tech (ATI) was upgraded to buy from hold at KeyBanc.
• Manhattan Associates (MANH) was upgraded to buy from hold at Benchmark.

After the closing bell Tuesday, Abbott Laboratories (ABT) announced that it will acquire Facet Biotech (FACT) for $27 per share. The transaction carries a total price tag of $722 million. Including $272 million of FACT's cash and securities, the net cost turns out to be roughly $450 million.

Back in December, FACT turned down Biogen Idec's (BIIB) unsolicited takeover offer of $17.50 per share. The deal is expected to close in the second quarter, as both boards of directors have approved the deal.

Analyst Upgrades

• UBS upgraded Yum! Brands (YUM) to buy from neutral, citing valuation, improving momentum and stabilizing China fast-food sales. The firm raised its target to $44 from $38.
• United Technologies (UTX) was upgraded to outperform from neutral at Cowen.
• Needham upgraded Arris (ARRS) to buy from hold, citing valuation and positive near-term business trends. The firm has a $16 price target on shares.
• Warnaco (WRC) was upgraded to outperform from neutral at Credit Suisse.
• Aetna (AET) was upgraded to neutral from underperform at BofA/Merrill.
• Nestle (NSRGY) was upgraded to overweight from neutral at JPMorgan.

Here are some highlights from this past week's earnings coverage on BloggingStocks:

• Abercrombie & Fitch Co. (ANF) received an analyst's upgrade ahead of next week's Q4 earnings report.
• Acer Inc. reported its highest quarterly earnings in almost three years due in part to growth in shipments.
• Baidu Inc. (BIDU) swung to a better-than-expected Q4 profit, with strong revenue growth, and offered rosy guidance.
• Biogen Idec Inc. (BIIB) offered an upside surprise as well as full-year earnings above Wall Street estimates.
• Coinstar Inc. (CSTR) strong quarterly results and guidance, as well as litigation concerns, failed to inspire Wall Street.
• Coca-Cola Co. (KO) posted strong Q4 and full-year earnings results due to growth in emerging markets.

As my colleague Karla Yeh pointed out over at ONN.tv earlier today, Biogen Idec (BIIB) saw some unusual options trading in the wake of its positive earnings surprise before the bell.

BIIB gapped higher at the open, jumping almost 2% out of the gate. Less than a half hour into the trading day, large blocks of roughly 4,000 contracts each traded at four March strikes: the 45-strike put, the 50-strike put, the 55-strike call, and the 60-strike call. It appears as though this investor sold the March 50/55 strangle (the 50 put and the 55 call) and simultaneously purchased the March 45/60 strangle (the 45 put and the 60 call).

A short strangle is typically employed when the investor expects the underlying instrument to stay range-bound; a long strangle is used by traders who expect a sharp move in either direction. In this case, with one of each crossing the tape as part of one strategy, it can be referred to as an iron condor.

A late day rally kept the fear mongers from winning hand over fist today. We were down as much as 160 points and a buying spree came in rapidly. The 9.7% unemployment left more questions when you consider that the jobs creation lost another 20,000 jobs. Today's late-day rally seemed like bargain hunting at the end of the day or short sellers closing out of positions ahead of the weekend after big selling all week. The huge loss that it looked like was suddenly a day where the positive or negative close was not going to known until the final minutes.

Here were today's unofficial closing bell levels:

Dow 10,012.23 +10.05 (0.10%)
S&P 500 1,066.18 +3.07 (0.29%)
Nasdaq 2,141.12 +15.69 (0.74%)

Top Stock & Market Rumors
Top Analyst Upgrades/Downgrades

Analyst Upgrades

• Baird upgraded United Parcel Service (UPS) to outperform from neutral based on operating leverage, improving industry pricing and exposure to a cyclical recovery. The firm raised its target to $70 from $61.
• JMP Securities upgraded Qualcomm (QCOM) following positive wireless industry checks. The firm, which has a $60 target on the stock, believes Qualcomm is the best positioned wireless company to enable 3G deployments and the early ramp of 4G technology.
• Credit Suisse has taken a more positive stance on the potash sector given the settlement of the Chinese contracts and improving near-term fundamentals. The firm upgraded Potash (POT) to outperform from neutral and raised its price target to $135 from $119. Credit Suisse also raised Intrepid Potash (IPI) to neutral from underperform and raised its price target to $30 from $28.
• Avery Dennison (AVY) was raised to outperform from neutral at Baird.
• Biogen Idec (BIIB) was upgraded at BofA/Merrill to neutral from underperform.
• RadioShack (RSH) was upgraded to conviction buy from neutral at Goldman.